Oscotec discovers bone growth compound

Published: 2009-10-13 06:57:00

Updated: 2009-10-13 06:57:00

Oscotec Inc., a bone specialized biotech company based in Korea, says it has discovered a promising drug candidate to facilitate the bone growth under a two-year joint research with Harvard Medical School’s Institute of Chemistry and Cell Biology (ICCB), heralding a new breakthrough in osteoporos...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK